Higher‐risk myelodysplastic syndrome in an elderly patient: Long‐term partial remission with low‐dose prednisone, G‐CSF, and epoetin alfa

Currently, most patients with higher‐risk MDS are treated with 5‐azacitidine or decitabine. These agents are toxic. The treatment described here is safe, devoid of toxicity, fosters improved quality of life, and helps reduce transfusion requirements.

Detalles Bibliográficos
Autor principal: Islam, Anwarul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423084/
https://www.ncbi.nlm.nih.gov/pubmed/34512981
http://dx.doi.org/10.1002/ccr3.4752
Descripción
Sumario:Currently, most patients with higher‐risk MDS are treated with 5‐azacitidine or decitabine. These agents are toxic. The treatment described here is safe, devoid of toxicity, fosters improved quality of life, and helps reduce transfusion requirements.

Ejemplares similares